Methods for Preclinical Assessment of the Efficacy of Anticancer Medicines <i>in vivo</i> (Review)
INTRODUCTION. The main risk to the clinical translatability of preclinical results for anticancer medicinal products is posed by the difficulty of simulating clinical conditions in an experimental model. With only 5% of product candidates proving clinically effective, the search for new approaches t...
Uloženo v:
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2025-07-01
|
| Edice: | Регуляторные исследования и экспертиза лекарственных средств |
| Témata: | |
| On-line přístup: | https://www.vedomostincesmp.ru/jour/article/view/655 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
